Skip to main content

Table 4 Physician preference weights for (a) France; (b) Germany; (c) UK

From: Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom

Attribute Name Level Preference weight (95% CI) p value
(a) France
 Time until first SRE 28 months 1.44 (1.15, 1.72) 0.000
18 months − 0.13 (− 0.26, 0.01) 0.068
10 months −1.31 (− 1.60, − 1.02) 0.000
 Time until a 2-point increase in pain on the BPI 10 months 0.36 (0.18, 0.54) 0.000
6 months 0.18 (0.03, 0.33) 0.019
3 months −0.54 (− 0.72, − 0.36) 0.000
 Risk of ONJ each year None 0.15 (−0.02, 0.31) 0.086
1 out of 100 (1%) 0.22 (0.07, 0.37) 0.005
5 out of 100 (5%) −0.37 (−0.54, − 0.19) 0.000
 Risk of 0.5 mg/dL increase in baseline creatinine each year None 0.93 (0.68, 1.17) 0.000
4 out of 100 (4%) −0.07 (−0.23, 0.10) 0.427
10 out of 100 (10%) −0.86 (−1.09, − 0.64) 0.000
 Mode of administration Daily oral tablet 0.57 (0.35, 0.79) 0.000
Injection every 4 weeks 0.12 (−0.08, 0.31) 0.239
15-min infusion every 4 weeks −0.04 (− 0.24, 0.16) 0.677
120-min infusion every 4 weeks −0.64 (− 0.88, 0.40) 0.000
(b) Germany
 Time until first SRE 28 months 1.48 (1.19, 1.78) 0.000
18 months −0.31 (−0.47, − 0.16) 0.000
10 months −1.17 (−1.46, −0.88) 0.000
 Time until a 2-point increase in pain on the BPI 10 months 0.98 (0.70, 1.25) 0.000
6 months 0.04 (−0.12, 0.19) 0.649
3 months −1.01 (−1.19, −0.83) 0.000
 Risk of ONJ each year None 0.40 (0.22, 0.58) 0.000
1 out of 100 (1%) 0.27 (0.11, 0.44) 0.001
5 out of 100 (5%) −0.67 (−0.85, −0.50) 0.000
 Risk of 0.5 mg/dL increase in baseline creatinine each year None 0.80 (0.58, 1.01) 0.000
4 out of 100 (4%) 0.11 (−0.08, 0.29) 0.264
10 out of 100 (10%) −0.90 (−1.13, − 0.68) 0.000
 Mode of administration Daily oral tablet 0.30 (0.08, 0.52) 0.008
Injection every 4 weeks 0.41 (0.20, 0.63) 0.000
15-min infusion every 4 weeks 0.21 (0.01, 0.41) 0.042
120-min infusion every 4 weeks −0.92 (−1.16, − 0.68) 0.000
(c) UK
 Time until first SRE 28 months 1.25 (1.00, 1.51) 0.000
18 months −0.08 (−0.21, 0.06) 0.275
10 months −1.18 (−1.43, −0.92) 0.000
 Time until a 2-point increase in pain on the BPI 10 months 0.80 (0.59, 1.01) 0.000
6 months 0.17 (0.02, 0.32) 0.028
3 months −0.97 (−1.18, − 0.76) 0.000
 Risk of ONJ each year None 0.28 (0.13, 0.43) 0.000
1 out of 100 (1%) 0.37 (0.21, 0.53) 0.000
5 out of 100 (5%) −0.64 (−0.83, − 0.46) 0.000
 Risk of 0.5 mg/dL increase in baseline creatinine each year None 0.89 (0.68, 1.10) 0.000
4 out of 100 (4%) 0.07 (−0.10, 0.23) 0.434
10 out of 100 (10%) −0.96 (−1.17, − 0.74) 0.000
 Mode of administration Daily oral tablet 0.69 (0.47, 0.92) 0.000
Injection every 4 weeks 0.23 (0.05, 0.41) 0.011
15-min infusion every 4 weeks −0.13 (− 0.31, 0.06) 0.175
120-min infusion every 4 weeks −0.79 (−1.02, − 0.57) 0.000
  1. BPI, Brief Pain Inventory; CI, confidence interval; ONJ, osteonecrosis of the jaw; SRE, skeletal-related event
\